Article thumbnail

Summary characteristics of the studies included in the analysis.

By Margit Solymár (3356882), Ivan Ivic (3204495), László Pótó (4356955), Péter Hegyi (353118), András Garami (3356900), Petra Hartmann (844127), Erika Pétervári (3356909), László Czopf (5986070), Alizadeh Hussain (6009629), Zoltán Gyöngyi (3522683), Patrícia Sarlós (3308154), Mária Simon (4568482), Péter Mátrai (3356897), Bálint Bérczi (6009632) and Márta Balaskó (3356903)


<p>Summary characteristics of the studies included in the analysis.</p

Topics: Biochemistry, Molecular Biology, Pharmacology, Developmental Biology, Cancer, Science Policy, Chemical Sciences not elsewhere classified, weight loss, PROSPERO, cholesterol, CRD, EMBASE, blood lipid profile, LDL, 6 randomized placebo-controlled studies, body weight, CI, body weight change, RCT, body weight changes, meta-analysis Background Metformin, Type 2 diabetes, 60 years, metformin treatment
Year: 2018
DOI identifier: 10.1371/journal.pone.0207947.t001
OAI identifier:
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.